These 54 Big Blue Chips Are On the Move

During these busy times it pays to stay on top of the latest blue chip opportunities. Today's blog post is a great place to start with these updated ratings More 

Gilead Sciences, Inc. (GILD) Buys Nimbus Therapeutics Subsidiary for $1.2B

Gilead Sciences has announced that it will be acquiring Nimbus Therapeutics' Nimbus Apollo, Inc. subsidiary for up to $1.2 billion. More 

3 Biotech Stocks on the Verge of an Overdue Run (AMGN, GILD, REGN)

Biotech stocks are making a comeback, with these three biotech beauties boasting bottoming patterns suggesting the time to strike is at hand. More 

Why Freeport-McMoRan Inc (FCX), Gilead Sciences, Inc. (GILD) and Tesla Motors Inc (TSLA) Are 3 of Today’s Worst Stocks

Gilead Sciences, Inc. (GILD), Freeport-McMoRan (FCX) and Tesla Motors (TSLA) never even had a prayer of gains on Wednesday. More 

Gilead Sciences, Inc.: GILD Could Squeeze the Bears From Here

Gilead Sciences enjoyed a rally Monday along with the rest of the biotech sector. This breakout could be followed up by a short squeeze in GILD stock. More 

The iShares Nasdaq Biotechnology Index (ETF) (IBB) Is a Buy, But Not for Long

The iShares Nasdaq Biotechnology ETF (IBB) has yet to pull off something that other parts of the market have -- and that spells opportunity in IBB. More 

Gilead Sciences, Inc.: Short the Looming Value Trap in GILD Stock

GILD stock is looking ripe for the picking in biotech market that appears to be seeing a bounce, but Gilead is a value trap waiting to snap. More